The Molecular Diagnostics (MDX) Market Forecast 2015-2025

LONDON, October 19, 2015 /PRNewswire/ --

Opportunities for Leading Companies 

What can be expected from the Molecular Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
 
Our 223-page report provides 145 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2025? Our study forecasts revenues in the following Molecular Diagnostics (MDx) submarkets:
• Infectious disease testing
• Oncology Testing
• Blood screening
• Genetic testing
• Tissue Typing (HLA)

See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:
• US
• Japan
• Germany
• France
• Italy
• Spain
• UK
• China
• Brazil
• Russia

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

• India
• South Korea
• Mexico

Leading companies and potential for market growth
Overall revenue for the Molecular Diagnostics (MDx) market will reach $10.45bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. An ageing population and increasing incidence of chronic diseases, especially cancer, globally will drive sales to 2025.

Our work analyses the key companies in the market. See visiongain's analysis of 7 leading companies, including these:
• Roche Diagnostics
• Qiagen
• Hologic
• Becton, Dickinson & Company
• bioMérieux
• Cepheid
• Agilent Technologies

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook
• Analysis of assays and instruments currently on the market as well as pipeline products
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Molecular Diagnostics industry?
Our new report discusses issues and events affecting the Molecular Diagnostics market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of national markets
• Unclear regulatory landscape challenging new entrants and major market players alike
• Emerging technologies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How The Molecular Diagnostics (MDx) Market Forecast 2015-2025  report helps you
In summary, our 223-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the Molecular Diagnostics (MDx) market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for submarkets in each - discover prospects for leading assays and instrumentation in the following areas: Infectious Disease testing including Chlamydia Trachonomatis (CT), Neisseriae Gonnohroea (NG), Human Papillomavirus (HPV), HIV, Healthcare associated infections (MRSA & Clostridium Difficile) Hepatitis C (HCV) and Respiratory infections (including Influenza and RSV), Oncology Testing and companion diagnostics, Blood Screening, Genetic Testing (including Cystic Fibrosis testing, Thrombophilia testing, inflammatory disease testing and rare disease testing) and Tissue (HLA) typing.
• Revenue forecasts to 2025 for the leading regional markets - US, Japan, EU5, BRIC South Korea and Mexico
• Assessment of 7 leading companies - analysis of Molecular Diagnostic products, revenue, mergers & acquisitions, sales by region and upcoming product releases
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Molecular Diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1515/The-Molecular-Diagnostics-(MDx)-Market-Forecast-2015-2025

Companies Listed

Abbott Laboratories / Abbott Molecular
AdvanDx
Agilent Technologies
Alere
ArcherDx
ARGENE
Ariosa Diagnostics
Atria Genetics
Astute Medical
Autogenomics, Inc.
AvariaDx
Becton, Dickinson & Co. / BD Diagnostics
Bina Technologies, Inc.
BIOBASE
Biocartis
BioFire Diagnostics
bioMérieux
Bio-Reference Laboratories
bioTheranostics
Boehringer Ingelheim
Bristo Myers Squibb
CAPP Medical
Celera Diagnostics
Cepheid
Chugai Pharmaceuticals
Clarient
CLC Bio.
Cognoptix
COPAN
Crescendo Bioscience
Dako A/S
Danaher Corporation
DiaGenic
DiagnoCure
Dutalys
DxS
EliTechGroup Epoch Biosciences
Enzymatics
Exact Sciences Corporation
Exosome
Focus Diagnostics, Inc.
Foundation Medicine
GE Healthcare
GenCell Biosystems
Genia Technologies, Inc.
Genentech
Genomic Health
GeneWEAVE Biosciences, Inc.
Gen-Probe
Gilead Sciences
Great Basin Scientific, Inc.
Grifols
Hain Lifescience
HandyLab
Hologic
IGEN International
Illumina, Inc.
Ingenuity Systems
Infectio Diagnstic, Inc.
Intelligent Medical Devices, Inc.
Ipsogen
IQuum, Inc.
IRIS International, Inc.
Janssen Diagnostics, LLC
Kapa Biosystems
Keysight Technologies Inc.
KIESTRA Lab Automation BV
Luminex Molecular Diagnostics, Inc.
MDx Health
Merck
Meridian Bioscience, Inc.
Meso Scale Diagnsotics
Myriad Genetic Laboratories, Inc.
Nanosphere, Inc.
Nanostring Technologies
Novartis
Olerup SSP AB
One Lambda
OPKO
OriGene
Ortho Clinical Diagnostics
Osmetech Molecular Diagnostics
PrimeraDx
Prodesse, Inc.
Proteome Sciences
Qiagen
Quest Diagnostics, Inc.
Quidel Corporation
RAS Lifesciences Pvt. Ltd
Roche Diagnostics (F. Hoffmann-La Roche Ltd.)
Saladax Biomedical Inc.
Santaris Pharma A/S
Seragon Pharmaceuticals, Inc.
Siemens Healthcare Diagnostics
Signature Diagnostics AG
Texas BioGene Inc.
Thermo Fisher Scientific
Ventana Medical Systems, Inc.
Veridex, LLC

Organisations Mentioned in the Report

American Medical Association
FDA's Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
French Court of Auditors
National Institute for Health and Clinical Excellence (NICE)
Rospotrebnadzor Federal Monitoring Agency
Rashtriya Swasthya Bima Yojana (RSBY) - (Indian National Health Insurance Programme)
Seguro Popular (Mexican National Health Insurance Programme)
United Nations Population Division
US Centers for Disease Control and Prevention (CDC)
US Centers for Medicare and Medicaid Services (CMS)
US Congressional Research Service (CRS)
US Food and Drug Administration (FDA)
USPS (United States Postal Service)
US National Healthcare Safety Network (NHSN)
World Health Organisation (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com